Al-Sawaf O et al. Tislelizumab plus zanubrutinib in patients with Richter transformation: Primary endpoint analysis of the prospective, multi-center, Phase-II RT1 trial of the German CLL Study Group. ASH 2023;Abstract 204.

Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. EHA 2023;Abstract S145.

Allan J et al. Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG). ASH 2023;Abstract 3285.

Bennett R et al. SOHO State of the art updates and next questions | Mechanisms of resistance to BCL2 inhibitor therapy in chronic lymphocytic leukemia and potential future therapeutic directions. Clin Lymph Myeloma Leuk 2022;22(11):795-804. Abstract

Brown J et al. Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL). ASH 2023;Abstract 202.

Brown J et al. Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: Updated analysis from the BRUIN study. ASH 2023;Abstract 326.

Chirino A et al. Resisting the resistance: Navigating BTG mutations in chronic lymphocytic leukemia (CLL). Genes (Basel) 2023;14(12):2182. Abstract

Crombie JL et al. SAVE (safe accelerated venetoclax escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL. ASCO 2023;Abstract 7512.

Eyre TA et al. BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASCO 2023;Abstract TPS7583.

Follows G et al. First-line fixed-duration ibrutinib plus venetoclax (ibr + ven) versus chlorambucil plus obinutuzumab (clb + o): 55-month follow-up from the glow study. ASH 2023;Abstract 634.

Frustaci AM et al. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. ASCO 2023;Abstract 7502.

Fürstenau M et al. First-line venetoclax combinations in fit patients with CLL: 4-year follow-up and NGS-based MRD analysis from the phase 3 GAIA/CLL13 trial. ASH 2023;Abstract 635.

Fürstenau M et al. Long-term remissions with MRD-guided acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Follow-up efficacy and circulating tumor DNA analysis of the CLL2-Baag trial. ASH 2023;Abstract 203.

Ghia P et al. Relapse after first-line fixed duration ibrutinib + venetoclax: High response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 Captivate study. ASH 2023;Abstract 633.

Hillmen P et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): Interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24(5):535-52. Abstract

Hillmen P et al. Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: Report of the phase III UK NCRI FLAIR study. ASH 2023;Abstract 631.

Iyer P, Wang L. Emerging therapies in CLL in the era of precision medicine. Cancers (Basel) 2023;15(5):1583. Abstract

Jensen JL et al. The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol 2022;13:20406207221101697. Abstract

Kater A et al. Final 7-year follow up and retreatment substudy analysis of MURANO: Venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). EHA 2023;Abstract S201.

Kater A et al. Time-limited venetoclax and ibrutinib for patients with relapsed/refractory CLL who have undetectable MRD – 4-year follow up from the randomized phase II VISION/HO141 trial. EHA 2023;Abstract S148.

Langerbeins P et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): Final results of the phase 3, double-blind, placebo-controlled CLL12 trial. EHA 2023;Abstract S200.

Montoya S, Thompson MC. Non-covalent Bruton’s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers (Basel) 2023;15(14):3648. Abstract

Nakhoda S et al. Resistance to BTK inhibition in CLL and non-Hodgkin lymphoma. Br J Haematol 2023;200(2):137-49. Abstract

Reyes A, Siddiqi T. Targeting BCL2 pathways in CLL: A story of resistance and ingenuity. Cancer Drug Resist 2023;6(4):828-37. Abstract

Roeker LE et al. Fixed-duration pirtobrutinib combined with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Updated results, including MRD data, from the BRUIN phase 1b study. ASH 2023;Abstract 3269.

Seymour JF et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood 2023;142(8):687-99. Abstract

Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN. ASH 2023;Abstract 636.

Siddiqi T et al. Lisocabtagene maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004. ASH 2023;Abstract 330.

Tam C et al. Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): Data from an ongoing phase 1/2 study. ASH 2023;Abstract 327.

Wierda W et al. Pirtobrutinib in Richter transformation: Updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN study. ASH 2023;Abstract 1737.

Wiestner A et al. Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study. ASH 2023;Abstract 201.

Woyach JA et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Cancer Discov 2024;14(1):66-75. Abstract

Woyach JA et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study. ASH 2023;Abstract 325.

Woyach JA et al. Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance). ASCO 2023;Abstract 7500.

Xu L et al. Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL without del(17p). ASH 2023;Abstract 1902.

Zhang J et al. Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomarker Res 2022;10(1):17. Abstract